Adalimumab in JIA-associated Uveitis Stopping Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

March 15, 2020

Primary Completion Date

January 23, 2025

Study Completion Date

April 3, 2025

Conditions
UveitisJIA
Interventions
BIOLOGICAL

Adalimumab

Adalimumab is a fully human monoclonal anti-tumor necrosis factor alpha antibody, a biologic, immunomodulatory drug. Adalimumab 20mg/0.8 mL and 40mg/0.8 mL is a clear, colorless solution provided in a pre-filled syringe for subcutaneous injection. The formulation is adalimumab, mannitol, polysorbate 80, and water for injection Each pre-filled syringe has a fixed 29-gauge thin wall and ½ inch needle with black protective cover and is intended for a single dose to a single patient.

OTHER

Placebo

The placebo solution is a clear, colorless solution provided in a single-use, pre-filled syringe for subcutaneous injection. The volume-matched (0.8mL) placebo is designed to match the characteristics of the citrate-free adalimumab during injection.

Trial Locations (21)

3052

Murdoch Children's Research Institute, Parkville

19104

Children's Hospital of Philadelphia, Philadelphia

33136

University of Miami, Miami

37212

Vanderbilt University Medical Center, Nashville

45229

Cincinnati Children's Hospital, Cincinnati

64108

Children's Mercy Hospital, Kansas City

78712

University of Texas, Austin, Austin

80045

University of Colorado Denver, Aurora

80228

Colorado Retina Associates, Lakewood

84132

University of Utah Health, Salt Lake City

94143

University of California, San Francisco, San Francisco

95817

University of California, Davis, Sacramento

BS1 3NU

University Hospitals Bristol and Weston, Bristol

Unknown

Cambridge University Hospital, Cambridge

University Hospitals, Leicester, Leicester

Manchester University NHS Foundation Trust, Manchester

L14 5AB

Alder Hey Children's Hospital, Liverpool

WC1N 3JH

Great Ormond Street Hospital, London

NE1 4LP

Great North Children's Hospital, Newcastle upon Tyne

NR4 6TZ

Norfolk and Norwich University Hospital, Norwich

S10 2TQ

Sheffield Children's Hospital, Sheffield

All Listed Sponsors
collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

Children's Hospital Medical Center, Cincinnati

OTHER

collaborator

Children's Mercy Hospital Kansas City

OTHER

collaborator

National Eye Institute (NEI)

NIH

collaborator

Great Ormond Street Hospital for Children NHS Foundation Trust

OTHER

collaborator

University Hospitals Bristol and Weston NHS Foundation Trust

OTHER

collaborator

Alder Hey Children's NHS Foundation Trust

OTHER

collaborator

Newcastle-upon-Tyne Hospitals NHS Trust

OTHER

collaborator

Sheffield Children's NHS Foundation Trust

OTHER

collaborator

Cambridge University Hospitals NHS Foundation Trust

OTHER

collaborator

Royal Children's Hospital

OTHER

collaborator

Norfolk and Norwich University Hospitals NHS Foundation Trust

OTHER

collaborator

Vanderbilt University Medical Center

OTHER

collaborator

University of California, Davis

OTHER

collaborator

University of Texas at Austin

OTHER

collaborator

University of Miami

OTHER

collaborator

University Hospitals, Leicester

OTHER

collaborator

University of Utah

OTHER

collaborator

Colorado Retina Associates

UNKNOWN

collaborator

Manchester University NHS Foundation Trust

OTHER_GOV

lead

Nisha Acharya

OTHER

NCT03816397 - Adalimumab in JIA-associated Uveitis Stopping Trial | Biotech Hunter | Biotech Hunter